Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs.

about

A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.

P2860

Q38383918-0CD7C5B3-96AC-43E1-BCE7-3F58E235B9D5

P2860

Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs.

Item

http://www.wikidata.org/entity/Q35783279

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs.

@ast

Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs.

@en

type

Item

label

Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs.

@ast

Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs.

@en

prefLabel

Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs.

@ast

Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs.

@en

P1476

Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs.

@en

P2093

Dai Watanabe

http://www.w3.org/2001/XMLSchema#string

Elisabeth A de Blieck

http://www.w3.org/2001/XMLSchema#string

Iwao Funahashi

http://www.w3.org/2001/XMLSchema#string

Kazunori Hosoe

http://www.w3.org/2001/XMLSchema#string

M Flint Beal

http://www.w3.org/2001/XMLSchema#string

Mitsuaki Kitano

http://www.w3.org/2001/XMLSchema#string

Padmaja Yerramilli-Rao

http://www.w3.org/2001/XMLSchema#string

P2860

Study on safety and bioavailability of ubiquinol (Kaneka QH) after single and 4-week multiple oral administration to healthy volunteers

Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.

Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.

Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects.

Mitochondria, oxidative damage, and inflammation in Parkinson's disease.

Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics.

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.

Risk assessment for coenzyme Q10 (Ubiquinone).

Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects.

Safety assessment of coenzyme Q10 (CoQ10).

P304

58-69

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1091581811425256

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Karl Kieburtz

Merit E Cudkowicz

P577

2012-01-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221768901

http://www.w3.org/2001/XMLSchema#string

P698

22267890

http://www.w3.org/2001/XMLSchema#string

P921

ubidecarenone

P932

3288259

http://www.w3.org/2001/XMLSchema#string

Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs.

about

P2860

P2860

Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932